A research collaboration was established in 2007 between the Belfer Institute of Applied Cancer Science and Merck & Co., Inc. to discover new cancer targets, define the biological context of those targets, and co-develop novel cancer therapeutics to reach those targets. In December 2010 the Belfer Institute and Merck agreed to extend the collaboration for two more years.
In 2010, the Belfer Institute of Applied Cancer Science and Sanofi-Aventis also established a cancer research alliance focused on identification and validation of novel cancer targets, discovery of novel therapeutics and associated biomarkers.
In the News
Study reports first success of targeted therapy in most common genetic subtype of non-small cell lung cancer